Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04592887
Other study ID # VAR-2019-02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 3, 2020
Est. completion date March 27, 2023

Study information

Verified date September 2023
Source Varian, a Siemens Healthineers Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This purpose of this study is to assess the feasibility of FLASH radiotherapy for the palliative treatment of painful bone metastases. FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.


Description:

This clinical investigation is designed to assess the workflow feasibility of FLASH radiotherapy treatment in a clinical setting, as well as the toxicities, and pain relief when used to treat bone metastasis(-es) in the extremities (excluding feet, hands, wrists). FLASH radiotherapy has been shown in preclinical studies to cause less injury to surrounding normal tissues during radiation treatment, while still having similar tumor cell killing. Patients at least 18 years of age with painful bone metastases located in the limbs will be considered for the study. These patients represent an ideal population for a feasibility study of FLASH radiotherapy as they are known to benefit from the palliative effects of radiotherapy using single dose radiation regimens of 8Gy which is what is being used in this investigation. After treatment, patients will be assessed for pain response as well as any adverse side-effects of radiation. The workflow feasibility of the treatment will also be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date March 27, 2023
Est. primary completion date March 27, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient age at least 18 years - Up to 3 painful bone metastasis(-es) in the extremities - Bone metastases that can be treated using pre-defined treatment field sizes (7.5 cm x 7.5 cm; 7.5 cm x 10 cm; 7.5 cm x 12 cm; 7.5 cm x 14 cm; 7.5 cm x 16 cm; 7.5 cm x 18 cm; 7.5 cm x 20 cm), without overlap of radiation fields - Life expectancy of >2 months (in the judgement of the investigator) - Patients who are able to comply with the protocol - Provision of signed and dated informed consent form Exclusion Criteria: - Prior radiotherapy to the treatment site(s) - Lesions of the feet, hands, wrists are not eligible treatment sites for FLASH - More than 3 painful bone metastases of the limbs requiring palliative radiotherapy - Tumor lysis of >50% of the circumferential bone cortex, or other factors considered to place the subject at significant risk of pathologic fracture - Patients with bone fractures and/or metal implants in the treatment field - Patients who will receive cytotoxic chemotherapy within 1 week prior to or 1 week following their planned radiation treatment - Prior local therapy modality to the treatment site(s) within 2 weeks of study enrollment - Patients with pacemakers or other implanted devices at risk of malfunction during radiotherapy - Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation - Patients at known risk of enhanced normal tissue sensitivity to radiotherapy due to inherited predisposition or documented comorbidity that might lead to hypersensitivity to ionizing radiation - Patients enrolled in any other clinical studies the investigator believes to be in conflict with this clinical investigation. - Patients who are pregnant or nursing

Study Design


Intervention

Radiation:
FLASH Radiotherapy
FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.

Locations

Country Name City State
United States Cincinnati Children's Proton Therapy Center Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
Varian, a Siemens Healthineers Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Workflow feasibility Treatment for an individual subject will be deemed NOT feasible if total treatment time on table is greater than one hour . Will be assessed on day of treatment delivery which occurs within 3 weeks of subject enrollment.
Primary Workflow feasibility Treatment for an individual subject will be deemed NOT feasible if delays in study treatment of more than 7 business days from simulation to treatment occurs related to the investigational device (excluding delays due to patient or facility factors not related to study treatment) Will be assessed within 4 weeks of subject enrollment.
Primary Assessment of radiation-related toxicities that are possibly, probably, or definitely related to FLASH radiotherapy. Toxicities that are possibly, probably, or definitely related to FLASH radiotherapy. Toxicities will be classified per CTCAE version 5.0. Assessed from start of treatment until subject death or lost to follow-up
Secondary Pain relief Patient reported pain score overall and specifically for treated sites. Assessed at Day 15, Months 1, 2, 3, long term; flare in bone pain assessed during the first 10 days after treatment
Secondary Use of pain medication. Use of pain medication. Assessed at baseline and for the first 10 days after treatment.
See also
  Status Clinical Trial Phase
Completed NCT01833806 - A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain N/A
Terminated NCT01586273 - Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases N/A
Completed NCT02609828 - Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy Phase 3
Recruiting NCT02231476 - Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients Phase 2
Recruiting NCT02426697 - Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy Phase 3
Completed NCT00334139 - Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Phase 4
Completed NCT01784393 - Chemoradiation for Bone Metastasis Phase 2
Terminated NCT02999152 - Validation of Radio-induced Damage Biomarkers N/A
Not yet recruiting NCT02480634 - Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer Phase 4
Completed NCT02784652 - Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors Phase 2
Completed NCT02673060 - A Trial of MBC-11 in Patients With CIBD Phase 1
Completed NCT02774213 - A Study to Collect Data About Analgesia in Patients With Bone Metastasis
Completed NCT02876731 - Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS) N/A
Recruiting NCT02705157 - The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones N/A
Completed NCT01309048 - Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases Phase 1/Phase 2
Completed NCT01062503 - Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC N/A
Completed NCT00610272 - Optimization of Radiotherapy in Treatment of Painful Bone Metastasis Phase 3
Completed NCT01998607 - Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw N/A
Recruiting NCT02876991 - Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma N/A
Completed NCT02293642 - Bone Pain Score Validation Initiative